The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring its effectiveness, according to Yale research published in JAMA Network Open.

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Under direction of Health Secretary Robert F. Kennedy Jr., the CDC is considering changes to its recommendations on vaccines ...

ATLANTA (AP) — A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. The ...

Members of the Advisory Committee on Immunization Practices voted to expand the options for meningococcal vaccines and to ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

For the first time since Robert F. Kennedy Jr. became health secretary, vaccine advisers to the CDC are meeting to discuss vaccines for RSV, HPV, COVID and more.

better known as RSV. According to the CDC, RSV is the leading cause of infant hospitalization in the U.S. It’s estimated that 58,000-80,000 children younger than five years old are hospitalized ...